Researchers disclosed that targeting interleukin‑2‑inducible T‑cell kinase (ITK) enhances the efficacy of anti‑CD19 CAR‑T cells by remodeling T‑cell signaling and function. The preclinical work indicates ITK modulation can improve persistence and antitumor activity in hematologic malignancies, suggesting a translational opportunity to combine small‑molecule kinase targeting with engineered cell therapies. If replicated in clinical studies, the approach could expand the therapeutic index of CAR‑T products and address resistance mechanisms tied to T‑cell dysfunction.